22肝胆膵_抄録_1_ indd
|
|
|
- きみお つつの
- 5 years ago
- Views:
Transcription
1 :30 12: PO001-1 PO001-2 I II 2cm MRI PO001-3 PO001-4 PO001-5 PO cm (Vp3/4,Vv2/3) PO PO001-8 B HCC C HCC B HCC PO :30 12: PO002-1 HDAC PO002-2 Down Staging 1 PO002-3 PO002-4 PO002-5 PO002-6 PO002-7 R0
2 :30 12:30 9 PO003-1 Virtual SonographyPTBDvirtual puncture line PO003-2 PO003-3 PO003-4 PO003-5 PO003-6 PO003-7 PO003-8 B PTBD Glasgow prognostic score GPS 3D-CT PTPE :30 12: PO004-1 ss PO004-2 PO004-3 PO004-4 PO004-5 PO004-6 PO004-7 PO004-8 Gemcitabine+TS-1 54 HPD 1 1 1
3 :30 12: PO005-1 PO005-2 PO005-3 PO005-4 PO005-5 PO005-6 PO PO :30 12: PO006-1 PO006-2 PO006-3 PO006-4 PO006-5 PO006-6 PO006-7 Ductile-penetrating method PO006-8
4 :30 12: PO007-1 no stent PO007-2 no stent PO007-3 PO007-4 PO007-5 PO007-6 PO007-7 PO007-8 PO :30 12: PO008-1 PO008-2 PO008-3 PO008-4 PO008-5 StageIV PO008-6 PO008-7 PO008-8
5 :30 12: PO009-1 PO009-2 PO009-3 PO009-4 PO009-5 PO009-6 PO009-7 FOLFOX/Bevacizumab :30 12:30 9 PO010-1 well differentiated endocrine tumor, uncertain behavior 1 PO010-2 PO010-3 PO010-4 PO010-5 PO010-6 PO neuroendocrine tumors :30 12:30 9 PO011-1 TAE
6 PO011-2 PO PO011-4 Kasabach-MerrittDiffuse Hepatic Hemangiomatosis PO011-5 PO011-6 PO :30 12: PO012-1 PO012-2 PO012-3 PO012-4 PO012-5 PO PO012-7 PO012-8 Fibrolamellar hepatocellular carcinoma :30 12:30 9 PO013-1 PO013-2 PO013-3 PO StageIV MRI
7 PO013-5 PO013-6 PMC QOL :30 12: PO PO014-2 PO014-3 PO014-4 PO014-5 PO014-6 PO014-7 PO014-8 PO014-9 Hemosuccus pancreaticus 2 SPT 1 Solid-pseudopapillary tumor 3 SPN solid-pseudopapillary tumor :30 12: PO015-1 S-1/Gemcitabine PO015-2 PO015-3 PO015-4 PO015-5 PO015-6 Gemicitabine/S-1 1 Gemcitabine+S-1 Gemcitabine R0 2 Gemcitabine 1 TS-1 1 Down-staging
8 PO R0Stage IVb :30 12:30 9 PO016-1 PO016-2 S-1 S-1 PO016-3 downstaging PO016-4 PO016-5 PO GFP 2 PO016-7 R - 1 PO :30 12:30 9 PO017-1 PO017-2 TAE PTPE B 1 IFN PO PO017-4 Lamivudine JA PO017-5 G-CSF 3 PO PO017-7 G-CSF PO017-8
9 PO :30 12:30 9 NASH, NAFLD PO018-1 NASH PO018-2 NASH PO018-3 PO018-4 NASH 1 PO018-5 PO018-6 C / PO018-7 PGE1 SMA PO018-8 PO018-9 Denver P-V :30 12:30 9 PO019-1 PO019-2 GIST 1 2 PO019-3 PO PO019-5 PO019-6 PO019-7 diffuse type HCC Vp3
10 PO019-8 PET :30 12:30 9 PO020-1 IPMN 1 PO020-2 PO020-3 PO PO020-5 JA PO PO020-7 PO :30 12:30 10 PO PO021-2 PO PO PO021-5 PO PO021-7 PO021-8 PO
11 :30 12: PO PO022-2 PO022-3 PO022-4 IPN-B 51 Intraductal papillary neoplasm of the bile duct IPNB 1 1 PO PO PO PO :30 12: PO023-1 PO023-2 PO023-3 PO023-4 PO023-5 PPPD SSPPD PO023-6 PO023-7 PO PO023-9
12 :30 12:30 10 IPMN -1 PO024-1 IPMN PO024-2 PO024-3 IPMN IPMN IPMN PO024-4 IPMN PO024-5 IPMN PO024-6 IPMN Cronkhite-Canada 1 PO PO :30 12:30 10 PO025-1 PO025-2 PO025-3 PO025-4 PO025-5 IPMT PD 2 PO PO025-7 PO025-8 IPMC 2 2
13 :30 12:30 10 PO026-1 PO PO026-3 PO026-4 WST-1viability assay PO026-5 PO026-6 MRI :30 12: PO PO027-2 Mirizzi 1 PO PO027-4 PO027-5 PO027-6 Mirizzi 1 PO PO PO :30 12:30 10 PO028-1
14 PO028-2 PO028-3 PO028-4 PO028-5 PO028-6 PO028-7 PO028-8 Segmental arterial mediolysis 1 TMA ADMTS13 PO :30 12: PO029-1 PO PO029-3 PO029-4 TS-1 1 PO PO029-6 mixed acinar-endocrine carcinoma 1 PO029-7 PO PO
15 :30 12: PO030-1 FFPE PO030-2 C PO PO030-4 PO030-5 Bcl-xL PO030-6 HSP(heat shock protein) PO030-7 GDF-8 PO030-8 CXC NF- B STAT3 PO030-9 hepcidin :30 12:30 10 PO031-1 PO031-2 VIO system PO031-3 PO031-4 FDG-PET PO AFP-L3 PO031-6 PO031-7 PO031-8 FDG PET-CT KL-6 MUC1 1
16 PO031-9 CT :30 12: PO032-1 PO032-2 PO032-3 PO032-4 PO IVR 1 covered stent biliary ablation1 1 PO032-6 PO PO PO :10 14:10 9 PO033-1 PO033-2 ICU PO033-3 Major hepatectomy PO033-4 GSA PO033-5 PO033-6 PO033-7 IDUS
17 :10 14:10 9 PO034-1 PO034-2 PO034-3 PO034-4 PO034-5 PO034-6 IPMN IPMN IPMN IPMN :10 14:10 9 PO035-1 PO035-2 PO035-3 immunonutrition randomized controlled study immunonutrition PO PO035-5 PO035-6 PO035-7 BCAA PO :10 14:10 9 SSI PO036-1 PO036-2
18 PO036-3 PO036-4 PO036-5 PO036-6 SSI PO036-7 PO036-8 SGA retrospective SSI :10 14: PO037-1 PO037-2 PO PO037-4 PO cm 21 1 PO PO :10 14: PO038-1 #16 PO038-2 PO PO038-4 PO038-5 Vater
19 PO038-6 PO038-7 PO038-8 PO S 1 1 S-1+CPT :10 14:10 9 NOTES, single port surgery-1 PO039-1 PO039-2 PO039-3 PO039-4 PO039-5 PO039-6 PO039-7 PO039-8 PO039-9 Single port surgery SPS Clipless pure single port cholecystectomy Single incision laparoscopic surgery SILS :10 14: PO PO040-2 PO040-3 PO040-4 PO040-5 ERGBD 2 15 LC VIDEO
20 PO040-6 PO040-7 PO040-8 PO :10 14: JA PO JA PO041-2 PO041-3 reactive lymphoid hyperplasia 1 PO PO041-5 PO041-6 TAE 1 15 PO PO PO :10 14:10 9 PO042-1 TissueLink Dissecting Sealer PO PO042-3 PO042-4 PO
21 PO042-6 ( ) PO042-7 ICG15 40 PO PO042-9 C IFN :10 14: PO043-1 PO043-2 PO043-3 PO043-4 PO043-5 PO043-6 PO043-7 hm RFA 1 B :10 14:10 9 PO044-1 PO044-2 PO044-3 PO044-4 FDG PET/CT PO044-5 p-stage I PO044-6 PO044-7
22 :10 14:10 9 DP-CAR PO045-1 PO045-2 PO045-3 DP-CAR DP-CAR Appleby 15 PO045-4 PO045-5 DP-CAR PO045-6 PO045-7 DPCAR 1 Appleby 1 PO045-8 appleby :10 14: PO PO PO PO046-4 PO PO046-6 PO046-7 PO046-8 PO IPMN
23 :10 14: PO PO PO047-3 PO047-4 Binf stage IV PO PO047-6 PO :10 14: PO PO048-2 von Recklinghausen GIST 1 PO048-3 FDG-PET 1 PO PO048-5 PO048-6 MRI 1 PO PO048-8 PO048-9 VIPoma WDHA SSTR2A LAR DTIC
24 :10 14: PO PO049-2 PO049-3 PO049-4 PO049-5 PO049-6 PO049-7 PO049-8 PO049-9 SPN Solid-pseudopapillary neoplasm Solid Pseudopapillary Tumor SPT 1 solid pseudopapillary tumor 1 Solid-pseudopapillary tumor SPT 1 Serous cystic tumor SCT islet cell tumor 2 FDG-PET solid pseudopapillary tumor :10 14: PO PO050-2 PO050-3 PO050-4 PO050-5 PO050-6 PO050-7 PO FDG-PET 1 1
25 :10 14:10 9 PO051-1 PO051-2 PO051-3 PO051-4 PO051-5 PO051-6 PO051-7 PO051-8 PO :10 14: PO052-1 PO052-2 PO052-3 PO052-4 PO052-5 PO052-6 PO Bismuth IV 1 1
26 :10 14: PO PO053-2 PO053-3 PO053-4 PO053-5 PO053-6 PO053-7 PO Reactive lymphoid hyperplasia of the liver 3 IgG :10 14: PO PO054-2 PO054-3 PO054-4 PO054-5 PO054-6 PO054-7 PO054-8 PO Postpancreatectomy hemorrhage delayed gastric emptying pancreatic duct patency Soft pancreas
27 :10 14:10 10 PO PO055-2 PO PO055-4 Duval PO055-5 PO055-6 PO055-7 PO055-8 groove pancreatitis 1 TAE Frey 1 PPPD PO :10 14:10 10 PO056-1 PO056-2 Multi Detector-row CT 3 PO056-3 PO056-4 PO MDCT MPR 3D-CT PO056-6 PO056-7 FDG-PET/CT
28 :10 14: PO PO057-2 PO057-3 PO057-4 PO057-5 PO057-6 PO057-7 PO :10 14: PO058-1 PO058-2 PO058-3 PO058-4 PO058-5 PO058-6 PO058-7 PO058-8 PO058-9 sorafenib Caveolin-1 T GIP Glucose-dependent insulinotropic peptide IL-1 HGF
29 :10 14:10 10 PO059-1 PO059-2 PO059-3 PO059-4 PO059-5 PO059-6 PO059-7 PO059-8 PO059-9 IIIb 1 1 3b :10 14: PO PO060-2 PO060-3 PO060-4 PO060-5 PO060-6 PO060-7 PO FOLFOX bevacizumab 2 PET-CT CR grade B,C FOLFOX /+bevacizumab S 1
30 :10 14:10 10 PO061-1 PO061-2 Confluence stone PO061-3 PO061-4 PO061-5 PO061-6 PO061-7 PO :10 14:10 10 PO062-1 PO062-2 PO062-3 Stage I II 3 Stage 0 II Stage 0-II PO062-4 PO062-5 PO062-6 PO062-7 IPMN PanIN 1 TS-1 PanIN PO PO
31 :10 14:10 10 IPMN -2 PO063-1 IPMC 1 PO063-2 PO063-3 PO063-4 IPMN 1 IPMN 19 IPMN 1 PO063-5 IPMN 5 IPMN 1 PO063-6 PO063-7 PO063-8 Invasive IPMC IPMN 3 PO063-9 MCN :10 14: PO PO064-2 FOLFOX 2 PO064-3 PO064-4 PO064-5 PO064-6 CR :00 14: PO065-1
32 PO065-2 CA19 9 Caroli PO PO065-4 PO PO065-6 PO PO :00 14: PO PO066-2 PO066-3 PO SI 1 PO066-5 PO066-6 PO066-7 MRI ADC PO066-8? :00 14: PO067-1 PO067-2 PO
33 PO067-4 B C PO067-5 PO067-6 PO067-7 FP vs. IFN/5FU PO PO :00 14: PO068-1 PO068-2 invasive micropapillary carcinoma 1 PO068-3 PO PO068-5 PO068-6 PO :00 14:00 9 PO069-1 C 1 PO069-2 PO069-3 Shunt binding Hassab1 PO PO069-5 Varicos-Caval H-graft
34 PO069-6 PO069-7 PO069-8 PO069-9 EVL 2 AT-III :00 14:00 9 PO070-1 PO070-2 PO070-3 PO070-4 PO070-5 PO070-6 AFP 1 AFP :00 14:00 9 NTT PO071-1 PE PO071-2 PO071-3 PO071-4 PO071-5 PO071-6 PO071-7 PO GIST 1 hemangiopericytoma 1 Humoral hypercalcemia of malignancy PTHrP1 29 GIST 1 GIST 1
35 :00 14: PO072-1 FNH 1 PO PO PO PO072-5 PO072-6 PO072-7 PO072-8 PO :00 14:00 9 PO PO PO PO PO073-5 PO073-6 PO073-7 DPCD Diffuse Polycystic Disease 1 3 polycystic disease 1 1 PO PO073-9
36 :00 14: PO074-1 KLF5 PO074-2 PO074-3 PO074-4 PO074-5 PO074-6 PO074-7 PO074-8 PO074-9 DNA Microsatellite CD45RO+ T Quercetin PDT Endotoxin Activity Assay :00 14: PO075-1 POSSUM SCORE PO075-2 PO075-3 PO075-4 PO075-5 PO075-6 PO075-7 PO075-8 PO075-9 MPD Index 1 IVR PD1
37 :00 14: PO076-1 PO076-2 PO076-3 PO076-4 PO076-5 PO076-6 PO076-7 PO076-8 PO076-9 Lemmel II Lemmel :00 14:00 9 PO077-1 CA19-9 PO077-2 PO077-3 PO077-4 PO077-5 PO077-6 PO077-7 PO077-8 PO077-9 Gemcitabine + TS-1 Gemcitabine TS-1R0/R1 gemcitabine 1 3 Gemcitabine, S-1 mfolfox6 10 1
38 :00 14:00 9 PO078-1 PO078-2 PO078-3 PO078-4 PO078-5 PO078-6 PO078-7 PO078-8 PO078-9 SPS single port surgery cholecystectomy PET :00 14: PO079-1 PO079-2 PO079-3 PO079-4 PO079-5 PO079-6 PO079-7 PO079-8 PO IPMN Stage I 1 SCN 5 solid variant type SCN 3 solid pseudopapillary carcinoma 1 3 solid and pseudopapillary tumor 1 1
39 :00 14: PO080-1 PO PO PO PO080-5 PO PO PO080-8 PO080-9 MRSA Groove pancreatic carcinoma :00 14:00 9 PO PO PO PO PO PO PO081-7 PO PO081-9 pancreatic groove carcinoma 1
40 :00 14:00 9 PO082-1 PO082-2 PO PO PO PO082-6 PO082-7 PO082-8 PO082-9 EMR :00 14:00 9 PO083-1 PO083-2 PO Lymphoepithelial cyst 1 PO Solid pseudopapillary tumor SPT PO PO083-6 PO083-7 Circumportal pancreas 2 PO083-8 PO
41 :00 14: PO084-1 PO PO PO PO PO084-6 PO :00 14:00 10 PO085-1 PO085-2 PO085-3 C 1 PO PO085-5 PO085-6 Hassab PO085-7 PO PO HCC
42 :00 14:00 10 PO086-1 PO spontaneous regression 1 PO086-3 PO086-4 HCC HBV-DNA HBc HCV Ia PO086-5 PO086-6 Spindle Cell type 1 3 PO086-7 PO086-8 PO :00 14:00 10 PO087-1 PO087-2 PO087-3 PO087-4 B3 1 C 1 3D PO087-5 S PO087-6 PO087-7 MRCP PO087-8 PO087-9
43 :00 14:00 10 NOTES, single port surgery-2 PO088-1 PO088-2 PO088-3 PO088-4 PO088-5 PO088-6 PO088-7 PO088-8 PO088-9 Single port surgery SILS Single incision laparoscopic surgery Single Incision Laparoscopic Surgery SILS SLIS Single Incision Laparoscopic Surgery Gas vs. Gasless single incision laparoscopic cholecystectomy single port surgery :00 14:00 10 PO PO089-2 PO089-3 PO089-4 PO089-5 PO089-6 PO089-7 PO IVR (PDE) 1 3 B
44 PO :00 14: PO PO090-2 PO090-3 PO090-4 PO090-5 PO090-6 PO090-7 PO (H3) 1 Cetuximab+CPT-11 1 FOLFOX4 1 mfolfox6 bevacizumab :00 14: PO091-1 GPS PO091-2 PO091-3 PO091-4 PO091-5 PO091-6 PO091-7 PO091-8 Venous drainage guided selective hepatectomy 1 S 9 1 FOLFIRI 1 adjuvant chemotherapy Life limiting nodule: LLN
45 :00 14:00 10 IPMN -3 PO092-1 IPMN 1 PO092-2 PO092-3 PO092-4 IPMN 4 IPMN 1 PO092-5 PO092-6 IPMN 1 PO PO092-8 IPMN PO092-9 IPMN :00 14: PO PO093-2 StageIII 1 PO093-3 PO093-4 S1 1 1 PO PO093-6 PO PO093-8 NBI
46 :00 14: PO PO PO PO094-4 PO094-5 PO094-6 PO094-7 TS-1 1 TS-1 1 S-1/Gemcitabine PO094-8 PO :00 14: PO095-1 PO095-2 IgG4 1 IgG4 1 PO095-3 PO PO095-5 Fluotine-18 fluorodeoxyglucose positron emission tomography PO095-6 PO095-7 PO IgG4 1
47 :00 14: PO PO096-2 PO096-3 PO PO PO PO096-7 PO096-8 Hepatopancreatoduodenectomy 38 PO
ÿþ
YV-18 YV-19 YV-20 HALS Surgrx Enseal System 5 29 16:10 17:10 1-1 YP-1 YP-2 YP-3 YP-4 YP-5 YP-6 1 20 TS1 2 5 29 16:10 17:10 1-2 YP-7 YP-8 YP-9 YP-10 YP-11 YP-12 1 IPMN 1 4 3 2 Gemcitabine 5 29 16:10 17:10
膵癌超音波診(案)
1 2 3 4 5 6 7 8 9 10 2009 7 6 2 a. invasive ductal carcinoma * 1 b. endocrine neoplasm c. Solid pseudopapillary neoplasm d. tumor producing pancreatitis * 2 * 1 invasive ductal carcinomas papillary adenocarcinoma
Professor Emeritus of Surgery, The University of Iowa College of Medicine Ken Kimura
51 3 2015 5 351 52 1 5 28 1 8 55 9 00 9 00 10 30 1 Keynote Lecture RS1-1 RS1-2 RS1-3S OCIAD2 DNA I RS1-4 Kif26A KO RS1-5 RS1-6S TLR-4 IL-4 DEC205 RS1-7S PGE-MUM 10 30 11 20 1 OS1-1 MAPK in vitro OS1-2
F A 1 13:00 14:00 O StageIV O O O O O ESD ,2, ,2 1,2 1,
11 1 1 11 1 11 1 1 1 2F A 1 13:00 14:00 O1-1 80 StageIV 7 5 2 O1-2 7 5 2 O1-3 857 5 2 O1-4 7 5 2 O1-5 857 5 2 O1-6 85 ESD 7 5 2 1,2,3 3 3 3 1,2 1,2 1,2 1 1 1 1 2 3 O1-7 90 7 5 2 O1-8 7 5 2 1 1 1 1 2 3
超音波40-5廣岡先生(膵癌)_念*.indd
1 2 3, 4, 5, 6, 7, 8, 9, 10 11,.2009 7 6,, 2.,,.,.,,,.,,,.,,,,.,,.,. a. invasive ductal carcinoma * 1 b. neuroendocrine neoplasm c. Solid-pseudopapillary neoplasm d. mass-forming tumor-producing pancreatitis
がん診療におけるFDG FDG-PET/CTの役割
PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT
日本消化器外科学会教育集会
200214 IPMT MCT 15 90 2000 6.5 1 Epithelial tumors Exocrine tumors Serous cystic tumors Mucinous cystic tumors Intraductal tumors Atypical hyperplasica(ah)and carcinoma in situ(cis) Invasive ductal carcinoma
核44-4 (ガイドライン)-1
FDG-PET (2007) PET FDG PET * 2 * PET FDG PET PET/CT PET PET PET PET PET PET PET CT PET QOL PET PET PET PET 2 1. 2. 3. 4. 5. 6. 7. 8. 9. 9-1) 9-2) 9-3) FDG-PET 9-4) 9-5) A. CT B. PET/CT 9-6) MRI 9-7) 10.
全国循環器撮影研究会 HP講座No
HP No.6 4 HP No.6 4 NTT 1. 1936 1953 Seldinger Seldinger 1956 Odman X Interventional Radiology IVR 1967 Margulis 1964 Dotter 2. 2.1 IVR CT MR IVR 2.2-1 - HP No.6 4 2.3 feeding artery parasitic supply increased
untitled
436 2112 12 436 2112 12 200912 12 800 900 1000 1100 1200 1300 1400 830 5F 900949 9491031 11051140 11401201 12061300 857900 10311050 10501105 13051340 13401422 5F 830 10301700 4F 403 11001150 5F 11551245
11 第25回がん学会一般演題一覧（第3会場）
1) 2) 1) 2) KTSND 2 200 KTSND KTSND 2014 4 CD56 Chromogranin Ki67 70% CT T2N4M0stage IVa /(egfr 55ml/min Cre 1.05mg/dl)/ PR 12 2015 4 CT 6 62 20XX 6 CTMRI 5 7 10 DIC methotrexatemtx /5-FU DIC score ALP
抄録_46回中国地方会37-6_責.indd
46 22 9 11 Update 46-1 Gd-EOB-DTPA MRI EOB-MRI HCC dysplastic nodule DN 146 62 146 123 HCC 23 DN B hypoechoic 67 46%hyperechoic 79 54% bright loop 14% A dynamic MDCT iso density EOB-MRI 24 B CT low density
092_41-1_23九州CS6_責.indd
2013 10 6 1, 2 3 4, 5, 4, 6, 3, 5, 1, 1 1, 2, 3, 4, 5, 6,70. 2011 7 CT, B C, -GTP,CEA CA 19-9.US,S 2 / 3 43 37 mm,. 11 mm,,.ceus,.,.,. 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 52. S 7 20 mm,. CT, CT, EOB MRI,T
2003 Giemsa HE HE AE1+AE3 HBME1 HE HE Well differentiated adenocarcinoma of colon Giemsa HE HE 62 Group V HE 47 Group V Peritoneal dissemination of gastric cancer HE 51 Poorly differentiated Adenocarcinoma(por2)
原著・報告・記録（４４行）／Ｐ１３４～１４７＿報告 肝移植症例登録
134 Vol. 52, No. 23 Liver transplantation in Japan. Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2016, a total of 8,825 liver
ito.dvi
1 2 1006 214 542 160 120 160 1 1916 49 1710 55 1716 1 2 1995 1 2 3 4 2 3 1950 1973 1969 1989 1 4 3 3.1 3.1.1 1989 2 3.1.2 214 542 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Surgeons, Gastroenterologists and Oncologists) (September 23-26, 2009, Beijing) Fluorouracil intra-arterial infusion combined with systemic gemc
1. Results of salvage esophagectomy after definitive chemoradiotherapy in patients with acrcinoma of the esophagus. Watanabe M, Yoshida N, Iwagami S, Toyama E, Hayashi N, Baba H ASCO GI Gastroentestinal
Microsoft Word - stage.doc
2009 4 6 General Rules for the Study of Pancreatic Cancer April 2009 (The 6th Edition) Japan Pancreas Society - 1 - I 1 II 2 III 3 1 3 1 3 2 4 3 5 4 5 2 7 1 7 2 10 3 11 IV 12 1 12 2 12 1 12 2 12 3 12 3
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
原著・報告・記録（４４行）／Ｐ１５６～１６９＿報告 肝移植症例登録
156 Vol. 50, No. 23 Liver Transplantation in Japan Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2014, a total of 7,937 liver
原著・報告・記録（４４行）／Ｐ２６１～２７４＿報告 肝移植症例登録
261 Liver Transplantation in Japan Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2013, a total of 7,474 liver transplants
₂₈ TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow B Flow. 2, , 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3
₂₈ 2016 10 22 23 TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow. 3. 1 B Flow. 2,. 3. 3 1, 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B.,.,,.,,. Depth 6 cm..,,,,.,. ₁ ₃,,,. 3,.3
日本消化器外科学会雑誌第23巻第2号
Key words: carcinoma of the pancreatic head, carcinoma of the periampullary region, operative results of the pancreatic duodenal carcinoma, mode of tumor spread of the pancreatic duodenal carcinoma, factors
S22 vol. 38 Suppl. 2013 38-3-2 38-3-3 38-3-4 38-3-5 JA 4 6 15 14:35 15:15 3 38-4-1 1 JA 38-4-2 10 38-4-3 38-4-4 5 5 6 15 15:20 16:10 3 38-5-1 1 38-5-2
vol. 38 Suppl. 2013 S21 1 6 15 11:25 12:15 4 38-1-1 38-1-2 US 38-1-3 1 38-1-4 38-1-5 2 6 15 13:40 14:30 3 38-2-1 1 38-2-2 38-2-3 CHI-Q 38-2-4 1 38-2-5 IgG4 3 6 15 13:40 14:30 4 38-3-1 S22 vol. 38 Suppl.
原著・報告・記録（４４行）／Ｐ１４５～１５９＿報告 肝移植症例登録
145 Liver Transplantation in Japan Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2015, a total of 8,387 liver transplants
第27回日本肝胆膵外科学会_プログラム抄録集1_150507.indd
1 6 11 15:00 15:50 1 1 座 長 : 青 木 武 士 ( 昭 和 大 学 消 化 器 一 般 外 科 ) P1-1 FDG-PET 渡 辺 亮 ( 群 馬 大 学 病 態 総 合 外 科 学 ( 第 一 外 科 )) P1-2 ICG-PDE 3 荒 井 淳 一 ( 長 崎 大 学 腫 瘍 外 科 ) P1-3 ICG 菅 原 秀 一 郎 ( 山 形 大 学 医 学 部 外 科
92 adenocarcinoma SE ly2 v2 n0 pstage KRAS XX XX 2 1 mfolfox6 l-lv 300 / L-OHP 130 / 5-FU 600 / 5-FU 3,600 / FU/LV de Gramont
92 91 95 2016 5-FU 1 1) 2) 3) 2) 2016 1 5 2016 3 4 FOLFIRI Bevacizumab Bev 5-FU NH3 1 NH 3 5-FU NH 3 Key words: 5-FU : NH 3 orotate phosphorylase OPRT thymidylate synthase TS dihydropyrimidine dehydrogenase
IVR232.indb
IVR Jpn J Intervent Radiol 23, 2008. 1 1 71 2 1 3D CTA DSA direct CCF 5 1CCF CCF 3D CTA 24 17/70 1999 1999 5 2004 12 92 83 76/92 1 1.3 1/76 93 71/76 1 1.3 1/76 370 CT 3 1 C3 2 C6 3 C5 1 1 1 546 2 1 2 3
untitled
1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,
1_2.eps
第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075
084_41-1_23四国CS6_念*.indd
2013 10 5 The forgotten chamber.,,,.1.2,,, 3,,. 4,CT,MRI,,,,,,,, fractional area change: FAC,,M tricuspid annular plane systolic excursion: TAPSE TAPSE < 16 mm., s, speckle tracking, Tei index,,,.,,,.,6,.,,,,,
GL_尾崎班_D.indd
Circulation Journal Vol. 72, Suppl. IV, 2008 1319 Churg-Strauss ANCA ANCA 1 1 1320 Circulation Journal Vol. 72, Suppl. IV, 2008 ANCA 1 ANCA ANCA 2 Circulation Journal Vol. 72, Suppl. IV, 2008 1321 2 2
02-06プ_一般ポスター_0407.indd
一般ポスター工学基礎一般ポスター工学基礎 イメージング 信号処理 5 月 7 日 ( 土 )6:0-7:0 ポスター 展示会場 座長 : ( 栃木県総合文化センター 階第 4 ギャラリー ) 90- 基 P-00 CT S6 90- 基 P-00 S6 90- 基 P-00 S6 90- 基 P-004 S6 90- 基 P-005 S64 90- 基 P-006 S64 90- 基 P-007 STC
学習内容と日常生活との関連性の研究－第１部－第３章
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 366 96 96 66 26 56 57 1 2 58 3 4 5 2004 59 6 70 7 60 9 10 61 366 23 23 15 GPS GPS 62 DNA DNA 63 1 GPS GPS 2004
untitled
5 10% 1 13 15cm 3 4cm 2 RS P Rb Ra S RS Ra Rb P 4 S RS CT MRI Stage 0 Stage I Stage I Stage II Ra Rb P TEM TEM ISR TEM Transanal endoscopic microsurgery 5cm 4cm 5cm TEM 1 2 3 10cm RS 6cm Ra 4cm Rb 2cm
JSACHD_Vol5_No3_Dec2016.book
5 3 12 16 (2016 ) Fontan 1) 2) 1) 2) Fontan circulation, Fontan associated liver disease, Liver fibrosis, Liver tumor, Central venous Pressure 25% I. FALD Fontan Fontan ( CVP) Fontan associated liver disease
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
Th1 four lines C1-dens 3mm C1-C4 C4 7mm C5-C7 C7 22mm
CC junction Th1 swimmer s s position 15 Th1 four lines C1-dens 3mm C1-C4 C4 7mm C5-C7 C7 22mm Log-roll 16 16 5.4 5.4 125 125 74.4 74.4 295 295 9 18.8 18.8 0 0 0 0 48 48 100 100 58 58 49.2 49.2 0 0 48 48
業績目録
. Kondo, K., Chijiiwa, Y., Otani, K., Kai, M., Ohuchida, J. and Chijiiwa, K.: Characteristics and surgical outcome of HCC patients with low platelet count. Hepato-Gastroenterology, : -,.. : -,.. Fujii,
03-07プ_一般口演_責*.indd
バブル キャビテーション 一 般 口 演 基 礎 5 月 9 日 ( 金 ) : 0-5 : 0 第 6 会 場 ( + ) 座 長 : 87- 基 -00 S6 87- 基 -00 S6 87- 基 -00 S65 87- 基 -00 S65 87- 基 -005 S66 組 織 音 響 特 性 5 月 9 日 ( 金 )5 : 50-7 : 00 第 6 会 場 ( + ) 座 長 : 87-
i
i ii iii iv v vi vii viii ix x xi ( ) 854.3 700.9 10 200 3,126.9 162.3 100.6 18.3 26.5 5.6/s ( ) ( ) 1949 8 12 () () ア イ ウ ) ) () () () () BC () () (
第１部 一般的コメント
(( 2000 11 24 2003 12 31 3122 94 2332 508 26 a () () i ii iii iv (i) (ii) (i) (ii) (iii) (iv) (a) (b)(c)(d) a) / (i) (ii) (iii) (iv) 1996 7 1996 12
42-2_26回関東甲信越地方会Pr6N_念*.indd
2014 10 18 19 TFT acoustic radiation force ARALA TI MI TI / MI TI / MI 1 2 3 4 5 1 2 3 4 5 PZT MASON 20 MRayl 20 MRayl 10 500 khz 20 MHz 1 mw 15 W 500 khz 20 MHz 100 W 60 MHz 1 2 3 4 5 4 6 6 4 1 2 3 4
Glucose Glucose FDG-PET CT MRI 3-iXCT
44 2 5 25 2005 2002 FDG-PET PET FDG-PET PET-CT PET positron 80 2 PET positron emission tomography 930 Warburg - FDG 2-deoxy-2-[ 8 F]fluoro- D-deoxy glucose FDG-6-2005 6 30 602-084 465 2FDG FDG-PET 2002
41-6_50回中国地方会Pr6N__HP掲載用.indd
2014 9 6 1, 2, 2, 2, 2 1, 2 60.. CT S 5 47 mm, 20 mm. US,,..,,. CT.,,.,. 8.,,.,. 1, 2, 2, 2, 2, 2, 3, 3 1, 2, 3 70 5,, CT. 17, 20, 30..,. Segmental Arterial Mediolysis SAM,.,. SAM,., 50,.,, 70. S 5 SOL.
第１章 国民年金における無年金
1 2 3 4 ILO ILO 5 i ii 6 7 8 9 10 ( ) 3 2 ( ) 3 2 2 2 11 20 60 12 1 2 3 4 5 6 7 8 9 10 11 12 13 13 14 15 16 17 14 15 8 16 2003 1 17 18 iii 19 iv 20 21 22 23 24 25 ,,, 26 27 28 29 30 (1) (2) (3) 31 1 20
CA CA19-9 CA19-9 CA CA CA19-9 ARCHITECT i 2000SR CLIA U/mL CA % CA CA
原 著 30 22-29, 2015 CA19-9 CA19-9 CA19-9 2006 12013 6 CA19-9 32,508 37.0U/mL 790 2 CA19-9 320 CA19-9 ARCHITECT i 2000SRCLIA 0.0 37.0U/mL 8 4 1 2 18CA19-9 198.2 46.4 2,968 U/mL 5 3 2.5% CA19-9 2.5% CA19-9
untitled
96 E-mail mizumi@tokyo-med.ac.jpmed.ac.jp 2008.6.28 1. 2. 3. 4. vs. 5. 6. 12, 16 Poroma / vs. 1. decapitation secretion apocrine snout apical snout pinching-off fringe 2. 3. 4. 5. 6.
44-1(前11)7回春季大会
PET 5 18 5 20 5 18 5 20 5 18 5 20 5 18 5 20 5 18 17:10 18:35 19 5 18 20 URL: http://www.t-inform.co.jp/jsnm-s7/ 7 http://www.t-inform.co.jp/jsnm-s7/ 7 19 5 18 20 7 7 PET PET PET RI 2 19 PET PET PET 1
表1票4.qx4
iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614
卵巣癌の治療
K-net:2008.7.17 85 90 8 10 20 (FIGO) a (FIGO) b (FIGO) c (FIGO) a (FIGO) b (FIGO) c (FIGO) (FIGO) (FIGO) Risk factors Preventive factors Risk factors 35 PCO, Preventive factors? Relative risk
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
gyouseki
. -A-. - -. -. Kondo K. Chijiiwa K. Ohuchida J. Kai M. Fujii Y. Otani K. Hiyoshi M. Nagano M. and Imamura N. Selection of prophylactic antibiotics according to the microorganisms isolated from surgical
肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
....outline.R...x.\..
ACAR Lecture Session-1 (Genitourinary system) ACAR SS-1 Genitourinary Tract-1 ACAR SS-2 Genitourinary Tract-2 ACAR Honorary Lecture -1 ACAR/JSAR Opening Ceremony ACAR SS-3 GI ACAR SS-4 Pancreas ACAR SS-5
untitled
1 Session 1 9 00 10 00 10 4 1 1-001 CBCT 1-002 CT 1-003 FOV 1-004 Area detector CT 1-005 CT Modulation Transfer Function 1 2 3 4 5 6 7 8 1-006 CT Noise power spectrum 1 2 3 4 5 67 8 Session 2 10 00 10
fiúàÕ53-3†E4_fiÁ‘W04_−Šfic.indd
Imaging Diagnosis of Sclerosing Cholangitis Toshifumi Gabata, M.D., 1) Dai Inoue, M.D., 1) Osamu Matsui, M.D., 1) Hiroki Tatsu, M.D., 2) and Yasunari Fujinaga, M.D. 3) 1) Department of Radiology, Kanazawa
provider_020524_2.PDF
1 1 1 2 2 3 (1) 3 (2) 4 (3) 6 7 7 (1) 8 (2) 21 26 27 27 27 28 31 32 32 36 1 1 2 2 (1) 3 3 4 45 (2) 6 7 5 (3) 6 7 8 (1) ii iii iv 8 * 9 10 11 9 12 10 13 14 15 11 16 17 12 13 18 19 20 (2) 14 21 22 23 24
生体ナノテク第4回_穴なし
!!!!!!!!!!!! TEM! SEM, AFM! 参考文献 最先端材料システム One Point! イメージング (共立出版) 実験がうまくいく 蛍光 発光試薬の 選び方と使い方! (羊土社) 非侵襲 可視化 技術ハンドブック (NTS) 講義と実習 生細胞蛍光 イメージング (共立出版) よくわかる生物電子 顕微鏡技術 (共立出版) (in vivo) - /! - MRI! - X! in
「産業上利用することができる発明」の審査の運用指針（案）
1 1.... 2 1.1... 2 2.... 4 2.1... 4 3.... 6 4.... 6 1 1 29 1 29 1 1 1. 2 1 1.1 (1) (2) (3) 1 (4) 2 4 1 2 2 3 4 31 12 5 7 2.2 (5) ( a ) ( b ) 1 3 2 ( c ) (6) 2. 2.1 2.1 (1) 4 ( i ) ( ii ) ( iii ) ( iv)
スライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
特集・総説・報告（４４行）／Ｐ０４５－０５５＿報告 日本肝移植研究会
45 Liver Transplantation in Japan in 2006 Part 2 Registry by the The Summary Four thousand three hundred thirty liver transplants have been performed as of December 31, 2006 in 59 institutions in Japan.
i ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13
Reviews Original Case reports 0.2 0.5 1.0 2.0 0.77 0.64 0.67 0.56 0.81 1.02 1.01 1.14 USA HIP Sweden Malmö Östergötland Kopparberg Stockholm Gothenburg UK Edinburgh Canada NBSS-1 RR=0.82 (0.72-0.95)
Microsoft Word 年度DPCによるSPECT検査動向に関する報告 _02表紙.doc
DPC SPECT 2 2013 9 DPC/PDPSDiagnosis Procedure Combination / Per-Diem Payment System 1 DPC DRG/PPS: Diagnosis Related Groups / Prospective Payment System 2003 2008 7 2008 DPC 2012 1,500 DPC SPECT 70% DPC
43
43 HK4001 X X 1949 Paatero 1 X MTF MTF 10 m 3,6,9mm MTF MTF 3mm,6mm,9mm MTF MTF X HK4004 200nm 950nm 600nm 760nm 850nm 960nm OH 600 900nm 600nm 800nm 44 HK4006 JPEG2000 CTF HK4007 40 X Mo Mo MTF ACR156
本文_P _セッション.indd
19 5 11 13:30 14 : 10 1 TAPP 5 11 11:30 12 : 20 1 Bogros space of Bogros Retzius space of Retzius 5 10 12:40 13 : 10 1 TEPP 5 10 13:10 13 : 40 1 IL - 1-1 Laparoscopic Hernioplasty development of technique,
178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21
I 178 II 180 III ( ) 181 IV 183 V 185 VI 186 178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21 4 10 (
Single slice helical CT CT 1 2005 1 4 1. CT Anti-Lung Cancer Association: ALCA 1-5) 1993 9 10 ALCA (Nawa 6) ) single slice helical CT 10mm CT 2. 1 (http://www.thoracic-ctscreening.org/jpn/index.html )
抄録36-6偶_中国_責.indd
45 21 9 12 1 45-1 3D 1 5 10 1 1 12 0 13 6 2D 2 2 3D 1 14 2 63g 11cm 2 3D x 3DCT 1 3D 45-2 FIUVV 3 10 FIUVV IUFD 2 FIUVV 33 35 MRI 36 8 22 1cm FIUVV 28 IUFD 45-3 Fetal intra-abdominal umbilical vein varixfiuv
04_ポスター.indb
般ポスター基礎超音波計測一般 一般ポスター基礎 6 月 8 日 ( 金 ):00 - :0 ポスター会場 ( 神戸ポートピアホテル B F 座長 : 9- 基 P-00 S790 9- 基 P-00 S790 9- 基 P-00 S79 Jing ZHU, 9- 基 P-00 S79 9- 基 P-005 S79 9- 基 P-006 CT S79 Wenjing WU 9- 基 P-007 HIFU
スライド 1
2016.2.6 病理学会中国四国支部スライドカンファレンス 膵病変への病理学的アプローチ 膵臓病変の病理診断膵癌取扱い規約改訂の最新情報も含めて 福嶋敬宜 ( ふくしまのりよし ) 自治医科大学病理学 病理診断部 / 科 膵病変への病理学的アプローチ 膵腫瘍の組織分類と取扱い 規約改訂状況も含めて ミニ トピック ( 膵癌の前駆病変 ) ADM, AFL 膵病変への病理学的アプローチ 膵病変への病理学的アプローチ
130 中井陽介 4. 膵嚢胞性腫瘍の診療ガイドライン膵嚢胞性腫瘍に対するガイドラインとしては,IPMN/ MCNの国際診療ガイドラインとして 2006 年にいわゆる Sendai Guideline 12) が, さらに 2012 年にはFukuoka Guideline 1) として改訂が行われ
埼玉医科大学雑誌第 43 巻第 2 号平成 29 年 3 月 129 総説 膵嚢胞性腫瘍ガイドラインをめぐって 超音波内視鏡診断 治療の役割 中井陽介 東京大学消化器内科 1. はじめに 近年, 日常臨床において膵嚢胞性病変に遭遇する機会が増えている. 特に健康診断 人間ドックで行われる画像検査あるいは他疾患の精査 経過観察で行われる画像検査などによって偶発的に診断される無症候性膵嚢胞性病変は増加の一途をたどっている.
cm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
1 II III IV V 1 2 3 4 5 56 56 6 7 8 9 10 11 1988(S.63) 12 13 14 15 1988(S.63) 16 1988(S.63) 17 1988(S.63) 1988(S.63) 18 19 20 21 22 23 24 25 26 27 28 18-III 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
10 12 13 16 17 26 26 31 32 33 33 35 37 38 39 42 43 44 2 15 5 15 57 17 16 4 16 4 2 JA 16 7 1 10 22 11 9 12 6 12 2 12 24 17 1 6 JA 3 4 5 16 7 1 6 ( ) ( ) 15 ( ) ( ) ( ) ( ) ( ) 16 3 35 37 1 93 223 ( ) 218
R EVIEW A RTICLES 膵 消化管神経内分泌腫瘍 (NET) 最近の動向 100 Obendorfer cancer like lesion Neuroendocrine tumor NET NET adenoma-carcinoma sequence NET NET 1 NET は稀な
膵 消化管神経内分泌腫瘍 () 最近の動向 100 Obendorfer cancer like lesion Neuroendocrine tumor adenoma-carcinoma sequence 1 は稀な疾患か? Yao 1986 2005 Work Japan 10 3.73.1 10 2.21.0 midgut 1/31/10 2 WHO 2000 cancer like lesions
Microsoft PowerPoint - MDCT講演会.松本.ppt
Multi-detector CT の臨床応用の概略 ー横隔膜下部ー 大分大学医学部腫瘍病態制御講座放射線医学松本俊郎 横隔膜下臓器における MDCT の役割 実質臓器 ( 肝, 膵, 腎 etc.) 管腔臓器 ( 胆嚢, 腸管 etc.) 支持組織 ( 腸間膜 etc.) US MRI Angiography MDCT RI 検査 (PET) Endoscopy 腹部 X-p ERCP * ERCP:
; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
16 MHC 2018; 25 (1) 参加費 1 2, , ,000 会議等 :00 13: :00 13: :20 会場地図 TEL JR 350 m 57
Major Histocompatibility Complex 2018; 25 (1): 56 82 抄録集 16 2018 3 3 7 2 4 43 TEL 06 6962 7001 594 1101 840 TEL 0725 56 1220 56 16 MHC 2018; 25 (1) 参加費 1 2,000 2 1,000 3 3,000 会議等 1 3 3 13:00 13:10 2 3